Abstract:Background: Alzheimer's disease (AD), the most prevalent type of dementia, still lacks disease-modifying treatment strategies. Recent evidence indicates that maintaining gut microbiota homeostasis plays a crucial role in AD. Targeted regulation of gut microbiota, including probiotics, is anticipated to emerge as a potential approach for AD treatment. However, the efficacy and mechanism of multi-strain probiotics treatment in AD remain unclear. Methods: In this study, 6-month-old senescence-accelerated-mouse-prone 8 (SAMP8) and senescence-acceleratedmouse-resistant 1 (SAMR1) were utilized. The SAMP8 mice were treated with probiotic-2 (P2, a probiotic mixture of Bifidobacterium lactis and Lactobacillus rhamnosus ) and probiotic-3 (P3, a probiotic mixture of Bifidobacterium lactis , Lactobacillus acidophilus , and Lactobacillus rhamnosus ) (1 x 10 9 colony-forming units) once daily for 8 weeks. Morris water maze (MWM) and novel object recognition (NOR) tests were employed to assess the memory ability. 16S sequencing was applied to determine the composition of gut microbiota, along with detecting serum short-chain fatty acids (SCFAs) concentrations. Neural injury, A beta and Tau pathology, and neuroinflammation level were assessed through western blot and immunofluorescence. Finally, potential molecular mechanisms was explored through transcriptomic analysis and western blotting. Results: The MWM and NOR test results indicated a significant improvement in the cognitive level of SAMP8 mice treated with P2 and P3 probiotics compared to the SAMP8 control group. Fecal 16S sequencing revealed an evident difference in the alpha diversity index between SAMP8 and SAMR1 mice, while the alpha diversity of SAMP8 mice remained unchanged after P2 and P3 treatment. At the genus level, the relative abundance of ten bacteria differed significantly among the four groups. Multi-strain probiotics treatment could modulate serum SCFAs (valeric acid, isovaleric acid, and hexanoic acid) concentration. Neuropathological results demonstrated a substantial decrease in neural injury, A beta and Tau pathology and neuroinflammation in the brain of SAMP8 mice treated with P3 and P2. Transcriptomic analysis identified the chemokine signaling pathway as the most significantly enriched signaling pathway between SAMP8 and SAMR1 mice. Western blot test indicated a significant change in the phosphorylation level of downstream AKT/GSK-3 beta between the SAMP8 and SAMR1 groups, which could be reversed through P2 and P3 treatment. Conclusions: Multi-strain probiotics treatment can ameliorate cognitive impairment and pathological change in SAMP8 mice, including neural damage, A beta and Tau pathology, and neuroinflammation. This effect is associated with the regulation of the phosphorylation of the AKT/GSK-3 beta pathway.

Amelioration of Serum Aβ Levels and Cognitive Impairment in APPPS1 Transgenic Mice Following Symbiotic Administration

Chronic administration of prebiotics and probiotics ameliorates pathophysiological hallmarks of Alzheimer's disease in a APP/PS1 transgenic mouse model

Gut-derived Β-Amyloid: Likely a Centerpiece of the Gut–brain Axis Contributing to Alzheimer’s Pathogenesis

Fecal Microbiota Transplantation Alleviated Alzheimer’s Disease-Like Pathogenesis in APP/PS1 Transgenic Mice

A new intestinal supplement 'Synbiotics' therapeutically regulates gut microbiota and activates PPARs pathway to inhibit Alzheimer's disease progression in mouse models

Transplantaion of Parabacteroides distasonis mitigated Aβ-associated changes in APP/PS1 mice via gut-brain interactions by attenuating neuroinflammation

Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels

Β‐glucan Attenuates Cognitive Impairment of APP/PS1 Mice Via Regulating Intestinal Flora and Its Metabolites

Gut microbiota regulate cognitive deficits and amyloid deposition in a model of Alzheimer’s disease

Slowing Alzheimer's disease progression through probiotic supplementation

Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism

Bifidobacterium Lactis Probio-M8 regulates gut microbiota to alleviate Alzheimer’s disease in the APP/PS1 mouse model

Whey Protein Hydrolysate Intervention Ameliorates Memory Deficits in APP/PS1 Mice: Unveiling Gut Microbe–short‐chain Fatty Acid–brain Axis

Effect of Probiotic Fungi Against Cognitive Impairment in Mice Via Regulation of the Fungal Microbiota-Gut-Brain Axis.

Exploring the microbiota-Alzheimer's disease linkage using short-term antibiotic treatment followed by fecal microbiota transplantation

Multi-strain Probiotics Ameliorate Alzheimer’s-like Cognitive Impairment and Pathological Changes Through the AKT/GSK-3β Pathway in Senescence-Accelerated Mouse Prone 8 Mice

Non-uinform gut microbiota alteration patterns associated with therapeutic outcomes in an Alzheimer's disease animal model

Dynamic distribution of gut microbiota during Alzheimer's disease progression in a mice model

Chronic-Antibiotics Induced Gut Microbiota Dysbiosis Rescues Memory Impairment and Reduces β-Amyloid Aggregation in a Preclinical Alzheimer’s Disease Model

Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice

Live and Heat-Inactivated Streptococcus thermophilus MN-ZLW-002 Mediate the Gut–Brain Axis, Alleviating Cognitive Dysfunction in APP/PS1 Mice